Evoke Pharma Inc. (EVOK)

[mlkrborn]

positive results $11.35
Evoke Pharma study reports positive results of Metoclopramide nasal spray for Gastroparesis in Diabetics (EVOK) : Co announced the publication of a study that found intranasal delivery of metoclopramide to be more effective in managing symptoms of diabetic gastroparesis compared to the marketed oral tablet formulation of metoclopramide. The Phase 2b study, which was published online ahead-of-print for an upcoming issue of Neurogastroenterology & Motility, enrolled 89 patients from six study sites throughout the United States. The multicenter, randomized, open-label, parallel design study was the first to compare the efficacy and safety of metoclopramide nasal spray to oral tablets in diabetic patients with symptoms of gastroparesis when dosed four times a day for 6 weeks.